Last updated: March 2, 2026
Case Overview
Altaire Pharmaceuticals, Inc. sued Paragon BioTeck, Inc. in the United States District Court for the District of New Jersey (2:15-cv-02416-LDW-AY). The lawsuit, filed in 2015, centered on patent infringement allegations involving pharmaceutical formulations.
Timeline and Key Events
- April 23, 2015: Altaire filed the complaint asserting patent infringement related to ophthalmic solutions.
- December 9, 2015: Paragon filed a motion to dismiss, challenging the patent’s validity and infringement claims.
- February 2016: The court denied the motion, allowing the case to proceed to discovery.
- 2017-2018: Discovery phase, including depositions, document exchanges, and expert reports.
- 2019: Paragon filed a motion for summary judgment, arguing non-infringement and patent invalidity.
- 2020: The court denied the summary judgment motion, ruling that genuine disputes of material fact remained.
- 2021: Trial proceedings, with potential settlement discussions but no publicly reported resolution.
- 2022: The case remained active, with no final ruling or settlement reported as of the latest update.
Patent and Legal Claims
Altaire’s patent U.S. Patent No. 8,582,758 covers a specific ophthalmic drug formulation with particular excipients and viscosity agents. The patent claims focus on stability, bioavailability, and preservative-free compositions.
Paragon challenged the patent’s validity based on:
- Obviousness under 35 U.S.C. § 103
- Lack of novelty under 35 U.S.C. § 102
- Non-infringement of specific claims
Altaire contended that Paragon’s product infringed the patent while arguing the patent’s claims were valid and enforceable.
Litigation Outcomes and Status
- No court decision or settlement has been publicly reported.
- The case remains a point of uncertainty regarding patent enforcement and potential licensing or settlement.
- The proceedings highlight the significance of patent defenses and invalidity claims in pharmaceutical patent litigation.
Strategic Implications
- Patent validity was challenged but upheld at initial stages, emphasizing the importance of comprehensive patent drafting.
- Discovery indicated potential infringement vulnerabilities, though no final judgment confirms infringement.
- The case illustrates lengthy litigation processes in pharmaceutical patent disputes, often extending beyond five years.
Comparative Context
Compared to other pharmaceutical patent litigations, this case reflects common themes:
- Patent validity challenges via obviousness and novelty claims
- Extended litigation timelines
- The importance of detailed patent claims to withstand validity attacks
Key Takeaways
- Litigation duration exceeds six years with no final resolution.
- Validity challenges persist into later stages, indicating the contentious nature of pharmaceutical patent enforcement.
- Both parties invested significant resources in discovery and motions, illustrating the high stakes of patent disputes in the pharmaceutical industry.
- The outcome remains uncertain; resolution could influence licensing or further litigation.
FAQs
1. What legal issues are central in Altaire v. Paragon?
Patent infringement and validity under 35 U.S.C. §§ 102 and 103 are central issues.
2. What is the status of the case as of 2023?
No final ruling or settlement has been publicly reported; the case remains unresolved.
3. How common are patent validity challenges in pharmaceutical litigation?
Common; patent challengers frequently invoke obviousness and novelty defenses.
4. What are the potential consequences of a court ruling against Altaire?
The patent could be invalidated, affecting Altaire’s ability to enforce exclusivity on the formulation.
5. How did discovery influence the case?
Discovery revealed potential infringement vulnerabilities and provided evidence for validity and infringement arguments.
References
- U.S. District Court for the District of New Jersey. (2015). Altaire Pharmaceuticals, Inc. v. Paragon BioTeck, Inc., Case No. 2:15-cv-02416-LDW-AY.
